S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
NASDAQ:MDVL

MedAvail (MDVL) Stock Forecast, Price & News

$1.65
-0.05 (-2.94%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.57
$1.71
50-Day Range
$0.79
$3.03
52-Week Range
$0.79
$14.59
Volume
1.54 million shs
Average Volume
6.59 million shs
Market Capitalization
$54.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
30 days | 90 days | 365 days | Advanced Chart
Receive MDVL News and Ratings via Email

Sign-up to receive the latest news and ratings for MedAvail and its competitors with MarketBeat's FREE daily newsletter.

MedAvail logo

About MedAvail

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, kiosk, and drive-thru solutions in the United States and Canada. It operates in two segments, Retail Pharmacy Services and Pharmacy Technology. The company's MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. It also owns and operates SpotRx, a retail pharmacy platform. As of December 31, 2021, the company had 81 MedCenter kiosks. MedAvail Holdings, Inc. is headquartered in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDVL
Employees
287
Year Founded
N/A

Sales & Book Value

Annual Sales
$22.13 million
Book Value
$0.58 per share

Profitability

Net Income
$-43.81 million
Net Margins
-198.00%
Pretax Margin
-197.99%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,691,000
Market Cap
$54.30 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/24/2022
Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

760th out of 1,426 stocks

Drug Stores & Proprietary Stores Industry

5th out of 9 stocks

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













MedAvail (NASDAQ:MDVL) Frequently Asked Questions

Is MedAvail a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MedAvail in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MedAvail stock.
View analyst ratings for MedAvail
or view top-rated stocks.

How were MedAvail's earnings last quarter?

MedAvail Holdings, Inc. (NASDAQ:MDVL) posted its quarterly earnings results on Thursday, March, 24th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.04. MedAvail had a negative net margin of 198.00% and a negative trailing twelve-month return on equity of 121.31%. During the same period in the previous year, the business posted ($0.57) earnings per share.
View MedAvail's earnings history
.

What guidance has MedAvail issued on next quarter's earnings?

MedAvail issued an update on its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.80 M-, compared to the consensus revenue estimate of $7.64 million.

What price target have analysts set for MDVL?

2 analysts have issued 1-year price objectives for MedAvail's shares. Their forecasts range from $8.00 to $9.50. On average, they expect MedAvail's stock price to reach $8.75 in the next year. This suggests a possible upside of 430.3% from the stock's current price.
View analysts' price targets for MedAvail
or view top-rated stocks among Wall Street analysts.

Who are MedAvail's key executives?
MedAvail's management team includes the following people:
  • Mr. Ryan Ferguson, Consultant (Age 47, Pay $389.7k)
  • Mr. Mark Doerr RPh, CEO & Director
  • Ms. Ramona Seabaugh, Chief Financial Officer
  • Mr. George Burrows, VP of Operations & Vendor Management
  • Matt Broome, Exec. VP & GM of Technology
  • Mr. Craig Holtgrave, Sr. VP of Sales & Marketing
  • Ms. Lisa Lutich, Chief HR Officer
  • Ms. Joan O'Rourke, Pres of SpotRx
  • Mr. Steven B. Hess R.Ph., Exec. VP & GM of SpotRx
  • Mr. Bob McClune, Sr. VP of Data & Analytics
What is MedAvail's stock symbol?

MedAvail trades on the NASDAQ under the ticker symbol "MDVL."

Who are MedAvail's major shareholders?

MedAvail's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (22.88%), BlackRock Inc. (1.63%), Vanguard Group Inc. (1.62%), State Street Corp (0.67%), Joel Isaacson & Co. LLC (0.06%) and Belvedere Trading LLC (0.00%).
View institutional ownership trends for MedAvail
.

Which institutional investors are selling MedAvail stock?

MDVL stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, BlackRock Inc., and Joel Isaacson & Co. LLC.
View insider buying and selling activity for MedAvail
or view top insider-selling stocks.

Which institutional investors are buying MedAvail stock?

MDVL stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., and Belvedere Trading LLC.
View insider buying and selling activity for MedAvail
or or view top insider-buying stocks.

How do I buy shares of MedAvail?

Shares of MDVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MedAvail's stock price today?

One share of MDVL stock can currently be purchased for approximately $1.65.

How much money does MedAvail make?

MedAvail has a market capitalization of $54.30 million and generates $22.13 million in revenue each year. The company earns $-43.81 million in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does MedAvail have?

MedAvail employs 287 workers across the globe.

What is MedAvail's official website?

The official website for MedAvail is www.medavail.com.

How can I contact MedAvail?

MedAvail's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at (905) 812-0023, via email at [email protected], or via fax at 973-348-5707.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.